PHASE 2 STUDY OF COMBIDEX IN AUXILIARY NODE STAGING IN BREAST CANCER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是评估Combidex MR成像在确定和定位转移性乳腺癌的淋巴结侵犯方面的初步效果。大量的临床前和临床研究表明，Combidex能够以高特异性识别癌症相关的淋巴结。这项研究将进一步评估Combidex MR正确识别和定位转移性乳腺癌腋窝淋巴结转移的能力。 人们希望用Combidex对淋巴结进行磁共振成像将是一种比目前可用的方法更有效地对乳腺癌相关的淋巴疾病进行成像的方法。这项研究的次要目标是确定Combidex如何改变原发乳腺肿瘤的磁共振成像外观。大约30-50名患者将从这个医学中心参加这项研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to assess the preliminary efficacy of Combidex MR imaging in defining and localizing nodal involvement by metastatic breast cancer. Numerous pre-clinical and clinical studies demonstrate that Combidex can identify cancer-involved lymph nodes with high specificity. This study will further evaluate the ability of Combidex MR to correctly identify and localize axillary nodal involvement by metastatic breast cancer. It is hoped that MR imaging of lymph nodes with Combidex will be a more effective procedure for imaging lymph node disease associated with breast cancer than the procedures that are currently available. The secondary objective of the study is to determine how Combidex changes the MR imaging appearance of primary breast tumors. About 30-50 patients will take part in this study from this medical center.